Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macuneos - Biophytis

Drug Profile

Macuneos - Biophytis

Alternative Names: BIO-201

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biophytis
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Stargardt disease
  • No development reported Age-related macular degeneration

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In the elderly, In volunteers) in France (PO)
  • 26 Jun 2019 Biophytis plans to hold a scientific advice meeting with EU regulatory agencies in the second half of 2019 regarding clinical development of macuneos (BIO201) for the potential treatment of dry AMD and Stargardt disease
  • 26 Jun 2019 Pharmacodynamics data from preclinical studies in Dry age-related macular degeneration and Stargardt disease released by Biophytis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top